Sitting in a parked car, phone propped up on the dashboard, recording, he takes a bite of his Chipotle bowl between sentences about a metabolic drug meant to make him eat less. Almost three months into retatrutide, he’s not sure it’s worth it anymore. The drug is still locked in Phase III clinical trials, nowhere near FDA approval, meaning sellers have no legal standing to market it for human consumption (Eli Lilly and Company 2026). He tells his viewers that he briefly looked into the gray market.  (read more...)